(JSPR) Jasper Therapeutics - Ratings and Ratios

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, specializes in developing innovative therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The companys lead product candidate, briquilimab, is a novel therapeutic antibody designed to clear hematopoietic stem cells from bone marrow in patients undergoing allogeneic stem cell therapy or gene therapy. This process aims to enhance the efficiency and safety of these treatments. Jasper Therapeutics focuses on addressing a range of conditions, including chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. Additionally, the company is advancing stem cell transplant therapies for rare genetic disorders such as sickle cell disease, Fanconi anemia, chronic granulomatous disease, GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics operates from its headquarters in Redwood City, California, and can be visited online at https://www.jaspertherapeutics.com/.

Based on the provided and , Jasper Therapeutics, Inc. (NASDAQ:JSPR) is currently trading at $5.53 with a 20-day average volume of 416,076 shares. The stock is below its 20-day and 50-day simple moving averages (SMA) of $5.96 and $9.92, respectively, while significantly below its 200-day SMA of $18.20. This indicates a bearish trend in the stock price over the past year. The Average True Range (ATR) of 1.04 suggests moderate volatility. From a fundamental perspective, the company has a market capitalization of $88.96 million and a price-to-book (P/B) ratio of 1.44, indicating that the market values the company slightly above its book value.